NASDAQ : QTRX

Quanterix Corporation

$2.42 USD

-$1.61 (-39.95%)

Volume
4M
Average Volume
1.03M
Market Capitalization
$114M
P/E Ratio
-0.92
Dividend Yield
0.00%
Price Target
$4.00
Year High
$8.77
Year Low
$2.15
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.40
Company Overview

NASDAQ

Everett V. Cunningham

Medical - Devices

Healthcare

QTRX

450

US

USD

https://www.quanterix.com

617 301 9400

74766Q101

0001503274

Liquidity Metrics

0.14

3.40

2.45

0.88

0.00

Sales & Valuation

$138.65M

0.74

0.48

-1.40

-1.74

Profitability

-$2.51

-$107.15M

-80.29%

-81.72%

-43.59%

-38.52%

P/E Metrics

-0.92

0.02

0.02

Analyst Price Target & Rating

$4.00

$4.00

$4.00

Neutral

3/5

10 Analysts

-39.50%

Financial Health Scores

-1.04

2/9

$135.82M

$366.67M

$84.53M

-$105.75M

Key Metrics (TTM)

$188.99M

1.30

-2.23

3.72

-35.17%

-36.13%

-55.03%

-43.67%

258 days

Company Executives
Name Title
Vandana Sriram Chief Financial Officer & Treasurer
Naren Bhat Senior Vice President of Corporate Development & Strategy
Erica Bell Chief People Officer
Everett V. Cunningham President, Chief Executive Officer & Director
Jason Faessler Chief Financial Officer & Treasurer
Anthony Catalano Chief Operating Officer
Daniel S. Char Chief Legal Officer & Corporate Secretary
David R. Walt Co-Founder & Chairman of Scientific Advisory Board
Joshua Young Head of Investor Relations
Jerzy Olejnik Chief Technology Officer
Michael Miller Chief Technology & Products Officer
William Donnelly Executive Chair
Poll Results

No votes yet today — be the first to share your view!

About Quanterix Corporation (NASDAQ:QTRX) Stock

Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiple ... x chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

2026-08-10 16:08:19

Quanterix Corporation (QTRX) Q2 2026 Earnings Call Transcript

Quanterix Q2 Earnings Call Highlights

2026-08-10 11:07:50

Quanterix NASDAQ: QTRX reported second-quarter 2026 revenue of $32.9 million and lowered its full-year outlook after management cited broad-based market softness and commercial execution challenges. The company said revenue came in about $3 million, or 9%, below the guidance it provided in May.

Quanterix Names Jim Gute Chief Commercial Officer

2026-08-10 08:01:00

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that seasoned healthcare executive Jim Gute has been appointed Chief Commercial Officer of the company. In this role, he will lead a re-acceleration of growth within the company's commercial operations. “We are thrilled to attract commercial leadership of Jim's caliber to Quanterix, at a pivotal time, ahead of our expansion in diagnostics and with renewed focu.

Quanterix Releases Financial Results for the Second Quarter of 2026

2026-08-10 08:00:00

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, today announced financial results for the second quarter ended June 30, 2026. “We made meaningful progress in the second quarter, including strengthening our leadership team and preserving cash better than planned. However, revenue fell short of our expectations, driven by execution challenges and continued market softness. We are taking immediate and significant action to im.

Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12

2026-08-06 08:00:00

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. Chief Executive Officer Everett Cunningham will engage in a fireside chat that will be webcast live on 1:00 pm ET on Wednesday, August 12th, during which he will provide an update on the C.

Quanterix To Report Second Quarter 2026 Financial Results on August 10, 2026

2026-08-04 08:00:00

Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August 10,

Quanterix: Trading Below 1x Sales Despite A Changing Story

2026-07-20 12:18:46

Quanterix is transitioning from persistent losses to a turnaround, driven by a new, highly experienced management team post-Akoya acquisition. QTRX targets cash flow breakeven in H2 2026, leveraging cost synergies, commercial execution, and a large installed base for recurring revenue. The Alzheimer's blood test and broader biomarker platform offer significant growth potential, though execution and adoption risks remain.

Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-07-16 16:05:00

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).

Frequently Asked Questions

What is the current Quanterix Corporation (QTRX) stock price?

Quanterix Corporation(NASDAQ:QTRX) stock price is $2.42 in the last trading session. During the trading session, QTRX stock reached the peak price of $8.77 while $2.15 was the lowest point it dropped to. The percentage change in QTRX stock occurred in the recent session was --39.95% while the dollar amount for the price change in QTRX stock was -$1.61.

QTRX's industry and sector of operation?

The NASDAQ listed QTRX is part of Medical - Devices industry that operates in the broader Healthcare sector.

Who are the executives of QTRX?

Vandana Sriram | Chief Financial Officer & Treasurer
Naren Bhat | Senior Vice President of Corporate Development & Strategy
Erica Bell | Chief People Officer
Everett V. Cunningham | President, Chief Executive Officer & Director
Jason Faessler | Chief Financial Officer & Treasurer

How many employees does QTRX have?

Number of QTRX employees currently stands at 450. QTRX operates from Building 1, Billerica, MA 01821, US.

Link for QTRX official website?

Official Website of QTRX is: https://www.quanterix.com

How do I contact QTRX?

QTRX could be contacted at phone #617 301 9400 and can also be accessed through its website. QTRX operates from Building 1, Billerica, MA 01821, US.

How many shares of QTRX are traded daily?

The average number of QTRX shares traded daily for last 3 months was 1.03M.

What is the market cap of QTRX currently?

The market value of QTRX currently stands at $114M with its latest stock price at $2.42